Glucagonoma syndrome.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  American Journal of Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0002-9343(87)90424-4PMID 2884877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995.

  1986cited by this paper
• Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue.

  1986cited by this paper
• Molecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas.

  1985cited by this paper
• [Glucagonomas. Clinical, biological, anatomopathological and therapeutic aspects (general review of 130 cases].

  1982cited by this paper
• In Vitro and In Vivo Studies on Glucagonoma Tissue

  1980cited by this paper
• Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

  1980cited by this paper
• Pancreatic glucagonoma with and without syndrome

  1980cited by this paper
• Clinical and Metabolic Aspects of Glucagonoma

  1980cited by this paper
• Pancreatic alpha cell tumors: Case report and review of the literature

  1980cited by this paper
• Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue.

  1979cited by this paper
• Possible entries to the diagnosis of a glucagon-producing tumour.

  1979cited by this paper
• Functional studies in patients with the glucagonoma syndrome

  1979cited by this paper
• The glucagonoma syndrome: surgically curable diabetes.

  1979cited by this paper
• Glucagon secretion during the development of insulin-secreting tumors induced by streptozotocin and nicotinamide.

  1979cited by this paper
• The glucagonoma syndrome.

  1978cited by this paper
• [Pancreatic islet cell tumors and their syndromes. II. Zollinger-Ellison syndrome, glucagonoma syndrome, multiple endocrine adenomatosis and islet cell tumors not obviously provable].

  1978cited by this paper
• Therapeutic embolization.

  1978cited by this paper
• Glucagonoma syndrome. Report of two cases and literature review.

  1977cited by this paper
• [Islet cell tumor with diarrhea and diabetes (glucagonoma?) associated with hyperparathyroidism. Long-term results of local-regional treatment with streptozotocin].

  1977cited by this paper
• Necrolytic migratory erythema and glucagon cell tumour of the pancreas: the glucagonoma syndrome. Report of two cases.

  1976cited by this paper
• Pancreatic polypeptide in insulinomas, gastrinomas, vipomas, and glucagonomas.

  1976cited by this paper
• Cure of insulin-dependent diabetes mellitus by removal of a glucagonoma.

  1974cited by this paper
• Proceedings: Plasma levels of amino acids and glucagon in patients with pancreatic glucagonomas.

  1974cited by this paper
• A glucagonoma syndrome.

  1974cited by this paper
• Necrolytic migratory erythema with carcinoma of the pancreas.

  1973cited by this paper
• Proceedings: The association of a specific skin lesion with islet-cell tumours of the pancreas.

  1973cited by this paper
• Glucagonoma as part of the polyglandular adenoma syndrome.

  1972cited by this paper
• Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function 1

  1971cited by this paper
• A2 cell pancreatic microadenomas in a case of multiple endocrine adenomatosis.

  1971cited by this paper
• [Glucagonoma].

  1970cited by this paper
• Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin.

  1968cited by this paper
• A CUTANEOUS SYNDROME ASSOCIATED WITH ISLET‐CELL CARCINOMA OF THE PANCREAS

  1967cited by this paper
• A glucagon-secreting alpha-cell carcinoma of the pancreas.

  1966cited by this paper
• Pancreatic A-Cell Tumor Associated with Severe Diabetes Mellitus

  1966cited by this paper
• [Metastasizing islet cell carcinoma of the A cell type in a case of pemphigus foliaceus with diabetes renalis].

  1960cited by this paper

• Hepatic PKA Mediates Liver and Pancreatic α-Cell Cross Talk

  2025cites this paper
• Necrolytic Migratory Erythema as the First Manifestation of Functional Conversion in a Glucagonoma: A Case Report

  2025cites this paper
• Islet hormones at the intersection of glucose and amino acid metabolism

  2025cites this paper
• Premortem diagnosis of a pancreatic neuroendocrine tumour (glucagonoma) in a captive North American river otter (Lontra canadensis).

  2025cites this paper
• Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development—A Comprehensive Review

  2024cites this paper
• GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

  2024cites this paper
• Advances in basic research on glucagon and alpha cells

  2024cites this paper
• Pancreatic neuroendocrine tumors: classification, diagnosis and treatment – A review of the most frequent neuroendocrine tumors

  2024cites this paper
• Insulin therapy among diabetic patients in rural communities of Sub-Saharan Africa: a perspective review

  2024cites this paper
• Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence

  2024cites this paper
• Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities

  2023cites this paper
• Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms.

  2023cites this paper
• Hepatic Glucagonoma in a Post-bariatric Female Patient: A Case Report

  2023influential citation
• Relation between WHO Classification and Location- and Functionality-Based Classifications of Neuroendocrine Neoplasms of the Digestive Tract

  2023influential citation
• Eritema necrolítico migratorio como manifestación de tumor neuroendocrino de páncreas. Valoración clínico-radiológica

  2022influential citation
• A Glucagonoma Presenting as Cerebral Vein Thrombosis and Diabetes

  2022cites this paper
• How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?

  2022cites this paper
• EUS-guided radiofrequency and ethanol ablation for pancreatic neuroendocrine tumors: A systematic review and meta-analysis

  2022cites this paper
• Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells

  2022cites this paper
• Glucagonoma syndrome with necrolytic migratory erythema as initial manifestation.

  2021cites this paper
• A glucagon analogue decreases body weight in mice via signalling in the liver

  2021cites this paper
• Complexities in the medical management of hypoglycaemia due to congenital hyperinsulinism

  2020cites this paper
• Acute onset of necrolytic migratory erythema mimicking an erythema multiforme

  2020cites this paper
• Patients with MEN1 are at an increased risk for venous thromboembolism VTE risk in MEN1.

  2020cites this paper
• Glucagon for hypoglycaemia treatment in type 1 diabetes

  2020cites this paper
• Cancer of the Endocrine System

  2020cites this paper
• An endocrine-hepato-muscular metabolic cycle links skeletal muscle atrophy and hyperglycemia in type 2 diabetes

  2020cites this paper
• Necrolytic Migratory Erythema: Complete Healing after Surgical Removal of Pancreatic Carcinoma.

  2019cites this paper
• Glucagon Receptor Signaling and Glucagon Resistance

  2019cites this paper
• Emergency pancreatic resection for glucagonoma associated with severe necrolytic migratory erythema

  2019cites this paper
• Unremitting chronic skin lesions: a case of delayed diagnosis of glucagonoma

  2019cites this paper
• Glucagonoma syndrome with atypical necrolytic migratory erythema.

  2019cites this paper
• Glucagon Control on Food Intake and Energy Balance

  2019cites this paper
• A rare case report

  2019cites this paper
• VIPoma, Glucagonoma, and Somatostatinoma

  2019cites this paper
• Glucagon receptor signaling in metabolic diseases.

  2018cites this paper
• Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours

  2018cites this paper
• Oxyntomodulin: Actions and role in diabetes

  2018cites this paper
• Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis

  2017cites this paper
• Necrolytic Migratory Erythema: A Forgotten Paraneoplastic Condition

  2017cites this paper
• Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

  2017cites this paper
• Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.

  2017cites this paper
• Glucagonoma syndrome: a review and update on treatment

  2016cites this paper
• Iatrogenic Necrolytic Migratory Erythema in an Infant with Congenital Hyperinsulinism

  2016cites this paper
• Necrolytic migratory erythema associated with fatty liver disease and the psuedoglucagonoma syndrome.

  2016cites this paper
• Necrolytic migratory erythema associated with fatty liver disease and the syndrome

  2016cites this paper
• Management of the hormonal syndrome of neuroendocrine tumors

  2016cites this paper
• Delayed diagnosis of glucagonoma syndrome: a case report

  2016cites this paper
• Lack of glucagon receptor signaling and its implications beyond glucose homeostasis.

  2015cites this paper
• Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity

  2015cites this paper
• Renal Transplantation Role of the Pathologist and Clinical Implications GASTROINTESTINAL MANIFESTATIONS OF HEPATIC DISORDERS Portal Hypertension Primary Sclerosing Cholangitis and Autoimmune Hepatitis Liver Transplantation GASTROINTESTINAL MANIFESTATIONS OF SKIN DISORDERS Bullous Disorders Epidermol

  2014cites this paper
• Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example.

  2014cites this paper
• Ligand-Directed AAVP to Deliver a Therapeutic Transgene to Neuroendocrine Tumors of the Pancreas

  2013cites this paper
• Necrolytic migratory erythema: a common cutaneous clue of uncommon syndromes.

  2013cites this paper
• Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

  2013cites this paper
• Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

  2013cites this paper
• Gastrointestinal h o r m o n es a nd a p u d o m as

  2013cites this paper
• Pancreatic neuroendocrine tumors

  2012cites this paper
• Is Necrolytic Migratory Erythema Due to Glucagonoma a Misnomer? A More Apt Name Might Be Mucosal and Intertriginous Erosive Dermatitis

  2012cites this paper
• Necrolytic Migratory Erythema as the First Manifestation of Glucagonoma

  2012cites this paper
• Cachexia and herbal medicine: perspective.

  2012cites this paper
• Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome.

  2012cites this paper
• The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors

  2011cites this paper
• Necrolytic migratory erythema with the absence of necrolysis

  2010cites this paper
• Pancreatic Endocrine Tumors

  2010cites this paper
• Le syndrome du glucagonome - entité rare mais typique : un cas genevois et revue de la littérature

  2010cites this paper
• A Case with Glucagonoma Syndrome

  2010cites this paper
• Nutrition and bullous skin diseases.

  2010cites this paper
• Neuroendocrine tumors of the pancreas.

  2009cites this paper
• Glucagonoma syndrome

  2009cites this paper
• Multimodality treatment of unresectable hepatic metastases from pancreatic glucagonoma

  2009cites this paper
• Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

  2008cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 379 Pancreatic Endocrine Tumourigenesis Genes of potential importance

  2008cites this paper
• Necrolytic Migratory Erythema Associated with Glucagonoma: A Report of 2 Cases

  2008cites this paper
• Clinicopathologic challenge

  2008cites this paper
• Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

  2008cites this paper
• A 47‐year‐old woman patient with refractory migratory erythema

  2008cites this paper
• Necrolytic migratory erythema without glucagonoma in a patient with short bowel syndrome

  2006cites this paper
• Glukagonom des Pankreas mit Progression in ein neuroendokrines Karzinom

  2006cites this paper
• Diagnostic challenge of glucagonoma: case report and literature review.

  2006cites this paper
• Pancreatic signals controlling food intake; insulin, glucagon and amylin

  2006cites this paper
• Erythema necrolyticum migrans

  2006cites this paper
• Necrolytic migratory erythema

  2006cites this paper
• Cutaneous manifestations in celiac disease.

  2006cites this paper
• Toxic epidermal necrolysis: current evidence, practical management and future directions

  2005cites this paper
• Eritema necrolítico migratorio asociado a glucagonoma

  2005influential citation
• Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides

  2005cites this paper
• Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update.

  2005cites this paper
• Treatment of endocrine pancreatic tumors

  2005cites this paper
• Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours

  2004cites this paper
• Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas.

  2004cites this paper
• The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth

  2004cites this paper
• Necrolytic migratory erythema: clinicopathologic study of 13 cases

  2004cites this paper
• Necrolytic migratory erythema: a cutaneous clue to glucagonoma syndrome

  2004cites this paper
• Clinical endocrinology and metabolism. Gut endocrine tumours.

  2004cites this paper
• [Glucagonoma revealed by necrolytic migratory erythema].

  2003cites this paper
• CUTANEOUS MANIFESTATIONS OF INTERNAL DISEASES

  2003cites this paper
• [Imaging of endocrine tumours of the pancreas].

  2003cites this paper
• Glucagonome révélé par un érythème nécrolytique migrateur

  2003cites this paper
• Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia.

  2003cites this paper